NIH to Evaluate New Data on Breast Cancer Screening in Younger Women

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 11
Volume 5
Issue 11

BETHESDA, Md-NIH plans a consensus development conference to assess the most recent data on the efficacy of mammography in screening women age 40 to 49 for breast cancer. The agency plans to convene the conference on January 21-23, 1997, on the NIH Bethesda campus.

BETHESDA, Md—NIH plans a consensus development conference to assess the most recent data on the efficacy of mammography in screening women age 40 to 49 for breast cancer. The agency plans to convene the conference on January 21-23, 1997, on the NIH Bethesda campus.

The consensus panel will consider data published since the National Cancer Institute's 1993 International Workshop on Screening for Breast Cancer. This will include a review of an unpublished meta-analysis carried out by Swedish cancer researchers.

Articles in this issue
Factor Analysis of New Symptom Scale in Breast Cancer Finds Six Clusters
AIDS Funding Increased for Fiscal '97
'Cancer Rates and Risks' Available
New Breast Cancer Patient Resource Is Available
Short-Term Metronidazole not Linked to Cancer
Various Capitation Models Are Available for Oncology Networks
NCI Urges full Disclosure of Cigarette Contents
Antifungal Resistance on the Increase
Fentanyl Patch Useful Alternative in Cancer Pain Patients
Analysis of Microvessel Density Predicts Extraprostatic Spread
Late Infection With Cytomegalovirus a Serious Problem in Bone Marrow Transplant Patients
FDA Panel Cancels HIV Drug Meeting
Klausner Cites Breast Cancer Progress in Jo Oberstar Lecture
Foundation Supports Legislation Backing Cancer Treatment Coverage
FDA Approves Xillix LIFE-Lung System
Recent Videos
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Related Content
Data from the phase 3 INAVO120 trial support the approval of inavolisib-based treatment for patients with PIK3CA+, ER+/HER2– disease in the EU.

Inavolisib Combo Receives EU Approval in PIK3CA+ ER+/HER2– Breast Cancer

Russ Conroy
July 24th 2025
Article

Data from the phase 3 INAVO120 trial support the approval of inavolisib-based treatment for patients with PIK3CA+, ER+/HER2– disease in the EU.

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

The regulatory decision is based on data from the phase 3 DESTINY-Breast09 results presented at the 2025 ASCO Annual Meeting.

T-DXd Granted Breakthrough Therapy Designation by FDA in HER2+ Breast Cancer

Roman Fabbricatore
July 18th 2025
Article

The regulatory decision is based on data from the phase 3 DESTINY-Breast09 results presented at the 2025 ASCO Annual Meeting.

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

2 Preventive Care and Screening Adherence Among Women Surviving Breast Cancer

2 Preventive Care and Screening Adherence Among Women Surviving Breast Cancer

Anthony Zisa;Marcelo Sleiman Jr;Muriel Statman;Duye Liu;Adina Fleischmann;Kenneth Tercyak
July 16th 2025
Article
3 Intraoperative Radiotherapy: Alive and Well in the Bronx

3 Intraoperative Radiotherapy: Alive and Well in the Bronx

Caroline Oska;Eleni Kohilakis;Jana Fox
July 15th 2025
Article